Mainstay Set To Launch ReActiv8 Neurostimulator In Germany
This article was originally published in Clinica
Mainstay Medical is ready to launch its ReActiv8 neurostimulator, starting in Germany, now that the implantable device has a CE mark for the treatment of chronic back pain, the company announced May 25.
You may also be interested in...
Mainstay Medical has sold its first ReActiv8 neurostimulator implant in Germany. The implant was performed by an orthopedic surgeon at the Catholic Hospital Koblenz-Montabaur in Koblenz, Germany.
Starts & Stops is a regular feature highlighting the Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions from the previous month. August's selection includes a few emerging innovators advancing into large pivotal trials for their game-changing technologies.
Competition in the retinal implant market heats up as Pixium CE marks its second-generation bionic vision system, designed to offer key advantages including higher resolution and explantability.